
|Articles|August 11, 2008
Cystoid macular oedema drug begins testing
IBI-20089, a drug candidate for the treatment of cystoid macular oedema (CME), has completed patient enrollment for initial clinical testing, according to the drug's manufacturer, Icon Bioscience Inc (IBI).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Beyond anti-VEGF: The next wave in retinal therapy
2
Trehalose-hyaluronate combination aids tear film after eyelid surgery
3
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
4
ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe
5




















